ACROBiosystems stands as a pivotal player in the pharmaceutical and biotechnology sectors, devoted to addressing challenges through cutting-edge tools and solutions spanning from discovery to clinical applications. Their array of life science tools caters to both research and clinical settings, ensuring seamless transitions. ACROBiosystems remains at the forefront of innovation, offering a range of products like recombinant proteins, antibodies, assay kits, GMP-grade reagents, and customized services, all geared towards simplifying and expediting the development of superior and more cost-effective medicines. In a realm where the intricate balance between iron and lipid metabolism governs cellular energy dynamics, the significance of iron in cellular functions cannot be overstated. Iron not only governs cellular respiration, DNA synthesis, and antioxidant responses in rapidly proliferating tumor cells but also plays a pivotal role in regulating metabolic signaling pathways. Recent studies have shed light on fatty acid oxidation (FAO) emerging as a favored energy source for certain tumor cells, particularly under specific conditions.
The interplay between iron homeostasis and lipid metabolic reprogramming in tumors adapting to energy-deficient environments to fuel growth remains a topic of ongoing research. A recent groundbreaking study published in PNAS by Zhejiang University has unraveled a novel pro-carcinogenic mechanism of transferrin (TF) in hepatocellular carcinoma (HCC) cells. The research delineated that under glucose deprivation conditions, the AMPK-dependent phosphorylation of transferrin at S685 unmasks its nuclear localization signal (NLS), facilitating its binding to importin α7 (IPOα7) and subsequent nuclear translocation. Once inside the nucleus, TF interacts with peroxisome proliferator-activated receptor alpha (PPARα), enhancing its stability and thereby ramping up FAO. At a molecular level, transferrin acts as a catalyst for the FAO process and drives liver cancer cell proliferation by upregulating iron-dependent prolyl hydroxylase domain-containing protein 2 (PHD2)-mediated PPARα hydroxylation at P87, which inhibits MDM2-mediated PPARα degradation. Notably, experiments involving TF S685A and NLS mutants, along with the introduction of the PPARα P87A mutation in mouse models, have shown a substantial reduction in PPARα-mediated FAO, leading to increased HCC cell apoptosis and impeding liver cancer progression.
Tags: biotechnology
Read more from news-medical.net